Statewide quality improvement project reduced excessive radiation treatments for bone metastases by 80%

The effort by the Michigan Radiation Oncology Quality Consortium reduced unnecessary medical procedures, and saved the time and resources of patients and families.

10:19 PM

Author | Ian Demsky

doctor in white coat scanning person in machine with words "lab note" written on yellow badge with blue font bottom right
Michigan Medicine

An effort by the Michigan Radiation Oncology Quality Consortium reduced excessive radiation treatments for bone metastases by 80% at health care centers across the state, according to findings published in Practical Radiation Oncology.

The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients' bones. Once a standard practice, the American Society for Radiation Oncology has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.

"The goal was to save medical resources as well as reduce the burden on patients," said study first author Elizabeth Jaworski, M.D., a house officer in the Department of Radiation Oncology at U-M. "Patients and their loved ones may have to miss work to get these treatments. There may be travel costs, parking costs — it all adds up. And studies have found that getting more treatments isn't likely to lower their cancer pain any better."

The Michigan Radiation Oncology Quality Consortium, a collaborative quality initiative funded by Blue Cross Blue Shield of Michigan and the Blue Care Network, made a push across its member sites to reduce the procedures in 2018. By the fall of 2020, the use of extended-fraction for bone metastases fell from nearly 15% to just over 3% at 28 radiation facilities across the state.

More extended treatment was likely to happen at non-teaching hospitals and among physicians who had been practicing longer, the study of more than 1,400 patients found.

"We were very pleased to see this effort have such an impact in Michigan. In some parts of the country, use is still higher than 15%," said senior study author James Hayman, M.D., M.B.A., a radiation oncologist at U-M and co-director of the quality consortium. "And, while more than 10 treatments may be appropriate in rare cases, we're continuing to look at ways to reduce the overall number of treatments even further."

Paper cited: "Contemporary practice patterns for palliative radiotherapy of bone metastases: Impact of a quality improvement project on extended fractionation," Practical Radiation Oncology. DOI: 10.1016/j.prro.2021.05.002


More Articles About: Lab Notes Radiation Oncology Cancer Treatment Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories women doc looking ay xray up on bright board
Health Lab
Simple changes in care reduced heart exposure during lung cancer radiation treatment
By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 
IV drip
Health Lab
Monitoring program flags cancer patients at risk of highly toxic chemotherapy side effects
Researchers from the University of Michigan Health Rogel Cancer Center have developed a monitoring system using a research genetics program to trigger alerts about cancer patients suspected to have the DPYD gene variant.
cancer cell yellow blue
Health Lab
Potato starch supplements could be solution to bone marrow transplant complications
University of Michigan Health Rogel Cancer Center scientists have found a potential solution for preventing a common and dangerous complication in patients that receive stem cell transplants from a donor’s blood or bone marrow.  
HistoSonics Edison platform
News Release
U-M Health to purchase Edison platform for histotripsy, following FDA approval
Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy
older person pouring pills into hand close up
Health Lab
Early findings suggest this cancer drug may be effective against advanced tumors caused by genetic mutations
Sparrow Health System, part of University of Michigan Health, experts release findings in a study of a cancer drug for patients with genetic mutations.
Health Lab
Tumor-destroying soundwaves receive FDA approval for liver treatment in humans
Michigan Medicine has developed a new technique that provides a non-invasive alternative to surgery, chemotherapy and radiation treatments for cancer.